Alnylam Pharmaceuticals, Inc - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 185

Alnylam Pharmaceuticals, Inc – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Alnylam Pharmaceuticals, Inc - Product Pipeline Review - 2012” provides data on the Alnylam Pharmaceuticals, Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alnylam Pharmaceuticals, Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Alnylam Pharmaceuticals, Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alnylam Pharmaceuticals, Inc - Brief Alnylam Pharmaceuticals, Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alnylam Pharmaceuticals, Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alnylam Pharmaceuticals, Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alnylam Pharmaceuticals, Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alnylam Pharmaceuticals, Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alnylam Pharmaceuticals, Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alnylam Pharmaceuticals, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alnylam Pharmaceuticals, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alnylam Pharmaceuticals, Inc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Alnylam Pharmaceuticals, Inc; Alnylam Pharmaceuticals, Inc - Key Therapeutics; Alnylam Pharmaceuticals, Inc - Pipeline Overview and Promising Molecules; Alnylam Pharmaceuticals, Inc - News; Alnylam Pharmaceuticals, Inc - Latest Updates; Alnylam Pharmaceuticals, Inc - Pipeline; Alnylam Pharmaceuticals, Inc - Discontinued/Dormant Projects

List of Tables
List of Figures
Alnylam Pharmaceuticals, Inc Snapshot
Alnylam Pharmaceuticals, Inc Overview
Key Information
Key Facts
Arena Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Arena Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Arena Pharmaceuticals, Inc. – Pipeline Products Glance
Arena Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Drug Profiles
ALN-APC Program
Product Description
Mechanism of Action
R&D Progress
ALN-HPN
Product Description
Mechanism of Action
R&D Progress
ALN-HTT
Product Description
Mechanism of Action
R&D Progress
ALN-PCS
Product Description
Mechanism of Action
R&D Progress
ALN-RSV01
Product Description
Mechanism of Action
R&D Progress
ALN-RSV02
Product Description
Mechanism of Action
R&D Progress
ALN-TTR01
Product Description
Mechanism of Action
R&D Progress
ALN-TTR02
Product Description
Mechanism of Action
R&D Progress
ALN-VSP
Product Description
Mechanism of Action
R&D Progress
Drug For Ovarian Cancer
Product Description
Mechanism of Action
R&D Progress
JCV RNAi
Product Description
Mechanism of Action
R&D Progress
Malaria Research Program
Product Description
Mechanism of Action
R&D Progress
Parkinson's Disease Development Program
Product Description
Mechanism of Action
R&D Progress
RNAi Therapeutic For HSV Infection
Product Description
Mechanism of Action
R&D Progress
RNAi Therapeutics Program
Product Description
Mechanism of Action
R&D Progress
Arena Pharmaceuticals, Inc. – Pipeline Analysis
Arena Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Arena Pharmaceuticals, Inc. – Pipeline Products By Target
Arena Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Arena Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates
Arena Pharmaceuticals, Inc. - Dormant Projects
Arena Pharmaceuticals, Inc. – Company Statement
Arena Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Arena Pharmaceuticals, Inc., Recent Developments
Arena Pharmaceuticals, Inc.- Press Release
May 10, 2012: Alnylam Presents Final Results From Phase I Clinical Trial Of ALN-TTR01 For Treatment Of Transthyretin-Mediated Amyloidosis
Apr 20, 2012: Alnylam Reports Positive Clinical Results For ALN-PCS For Treatment Of Severe Hypercholesterolemia
Mar 19, 2012: Alnylam Initiates Phase I Clinical Study Of ALN-TTR02 For Treatment Of TTR-Mediated Amyloidosis
Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam's ALN-VSP
Jan 06, 2012: Alnylam Files Clinical Trial Application For ALN-TTR02 For Treatment Of Transthyretin-Mediated Amyloidosis
Jan 04, 2012: Alnylam Presents Positive Results From Clinical Trial Of ALN-PCS Using Tekmira's LNP Technology
Jan 04, 2012: Alnylam Reports Positive Phase I Preliminary Clinical Results For ALN-PCS For Treatment Of Severe Hypercholesterolemia
Nov 02, 2009: Alnylam Presents New Pre-Clinical Data ALN-TTR, RNAi Therapeutic Treatment Transthyretin-Mediated Amyloidosis
Nov 02, 2009: Alnylam Presents New Pre-Clinical Data ALN-TTR, RNAi Therapeutic Treatment Transthyretin-Mediated Amyloidosis
Sep 15, 2009: Alnylam And Medtronic Presents New Late-Stage Pre-clinical Data On ALN-HTT For The Treatment Of Huntington's Disease.
Jul 20, 2009: Alnylam And Cubist Reports Complete Data From Phase II Study In Respiratory Syncytial Virus
Jun 18, 2009: Alnylam And Collaborators Presents New Pre-Clinical Research Findings On RNAi Therapeutics Targeting PCSK9
Jun 08, 2009: Alnylam And Cubist Report Preliminary Data From Phase II Study Of ALN-RSV01
Apr 03, 2009: Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer
Jan 23, 2009: Alnylam Receives Clearance From FDA To Initiate Phase I Study With ALN-VSP For The Treatment Of Liver Cancers.
Jan 21, 2009: Alnylam And Collaborators At Harvard Medical School Demonstrate In Vivo Silencing Of Key Genes Implicated In The Transmission Of Herpes Simplex Virus-2 (HSV-2)
Financial Deals Landscape
Alnylam Pharmaceuticals, Inc, Deals Summary
Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Alnylam Acquires RNAi Therapeutics Assets From Nucleonics
Venture Financing
Regulus Therapeutics Secures $20 Million In Series A Preferred Equity Financing
Partnerships
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam
AlCana Extends Co-Development Agreement With UBC And Alnylam
Alnylam And Medtronic Form Collaboration With CHDI Foundation
Alnylam Pharma Enters Into Agreement With Tekmira Pharma
Novartis Extends Agreement With Alnylam Pharma
Cubist Pharma Enters Into Co-Development Agreement With Alnylam
Alnylam Enters Into Research Agreement With Max Planck Institute
Novartis Extends Co-Development Agreement With Alnylam Pharma
Alnylam Pharma And Kyowa Hakko Form Alliance
Alnylam Pharma Forms Joint Venture With Isis Pharma
Alnylam Pharma Amends Agreement With Medtronic
Biogen Idec Enters Into Agreement With Alnylam
Tekmira Amends Research Collaboration With Alnylam Pharma
Alnylam Pharma Amends Its Collaboration Agreement With Merck
Alnylam Pharma Enters Into Collaboration Agreement With USAMRIID
Alnylam Pharma Enters Into Research Agreement With Inex Pharma
Alnylam Enters Into Co-Development Agreement With Novartis
Alnylam Enters Into Agreement With Novartis
Alnylam Pharma Enters Into Collaboration With University Of Georgia
Alnylam Enters Into Agreement With Cystic Fibrosis Foundation
Alnylam Enters Into Agreement With Medtronic
Merck Enters Into An Agreement With Alnylam Pharma
Alnylam Enters Into Agreement With Cenix Bioscience
Licensing Agreements
Bio-Rad Labs Enters Into An Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Inex Pharma
Alnylam Enters Into Licensing Agreement With Dharmacon
Alnylam Enters Into License Agreement With Hybridon
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Tekmira Pharma
The University of Queensland Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Mount Sinai School
Alnylam Pharma Enters Into Licensing Agreement With University of Queensland
Roche Expands Licensing Agreement With Alnylam
Alnylam Enters Into License Agreement With Koken
Alnylam Pharma Enters Into Licensing Agreement With Isis Pharma
Alnylam Pharma Enters Into Licensing Agreement With Calando Pharma
Takeda Pharma Enters Into Collaboration Agreement With Alnylam Pharma
Alnylam Pharma And Tekmira Pharma Enter Into Licensing Agreement
Alnylam Enters Into Agreement With Shanghai GenePharma
Alnylam Pharma Enter Into Licensing Agreement With GeneDesign
Roche Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement with Hayashi Kasei
Alnylam Enters Into Licensing Agreement With Inex Pharma
Alnylam Pharma Enters Into Licensing Agreement With Quark Pharma
Alnylam Enters Into Agreement With Calando
Alnylam Enters Into Agreement With Bioneer
Alnylam Enters Into Agreement With Immune Disease Institute
Alnylam Enters Into Agreements With Massachusetts Institute of Technology
Gen-Probe Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Integrated DNA Technologies
Alnylam Pharma Enters Into Licensing Agreement With QIAGEN
Alnylam And Isis Enter Into License Agreement With Stanford University
Alnylam Enters Into License Agreement With MWG Biotech
Nastech Pharma Enters Into Agreement With Alnylam Pharma
Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich
Alnylam Enters Into License Agreement With Eurogentec
Alnylam Amends Its Agreements With Max Planck Society
Alnylam Enters Into Agreement With Ambion
Alnylam Enters Into Agreement With Benitec
Alnylam Pharma Enters Into Licensing Agreement With GeneCare Research Institute
Alnylam And Isis Enter Into Licensing Agreement With Max Planck Society
Isis Pharma Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Enters Into License Agreement With RNAX
Alnylam Enters Into Licensing Agreement With Invitrogen
Alnylam Enters Into Licensing Agreement With Cell Signaling Technology
Equity Offering
Alnylam Pharma Announces Underwriters' Exercise Of Over-Allotment Option For $93 Million
Alnylam Completes Private Placement Of $1 Million With Novartis
Tekmira Completes Private Placement Of $5 Million With Alnylam
Alnylam Pharma Completes Private Placement Of $5 Million
Alnylam Pharma Completes Public Offering Of $103 Million
Alnylam Completes Public Offering Of $67 Million
Alnylam Pharma Completes Private Placement Of $5 Million
Alnylam Pharma Completes IPO Of $35 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Alnylam Pharmaceuticals, Inc, Key Information
Alnylam Pharmaceuticals, Inc, Key Facts
Arena Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Alnylam Pharmaceuticals, Inc – Pipeline by Stage of Development, 2012
Alnylam Pharmaceuticals, Inc – Monotherapy Products in Pipeline, 2012
Arena Pharmaceuticals, Inc. – Phase II, 2012
Arena Pharmaceuticals, Inc. – Phase I, 2012
Arena Pharmaceuticals, Inc. – Pre-Clinical, 2012
Arena Pharmaceuticals, Inc. – Discovery, 2012
Alnylam Pharmaceuticals, Inc – Pipeline By Therapeutic Class, 2012
Alnylam Pharmaceuticals, Inc - Pipeline By Target, 2012
Alnylam Pharmaceuticals, Inc – Pipeline By Route of Administration, 2012
Alnylam Pharmaceuticals, Inc – Pipeline Products By Mechanism of Action, 2012
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Arena Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Alnylam Pharmaceuticals, Inc, Subsidiaries
Alnylam Pharmaceuticals, Inc, Deals Summary
Alnylam Acquires RNAi Therapeutics Assets From Nucleonics
Regulus Therapeutics Secures $20 Million In Series A Preferred Equity Financing
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam
AlCana Extends Co-Development Agreement With UBC And Alnylam
Alnylam And Medtronic Form Collaboration With CHDI Foundation
Alnylam Pharma Enters Into Agreement With Tekmira Pharma
Novartis Extends Agreement With Alnylam Pharma
Cubist Pharma Enters Into Co-Development Agreement With Alnylam
Alnylam Enters Into Research Agreement With Max Planck Institute
Novartis Extends Co-Development Agreement With Alnylam Pharma
Alnylam Pharma And Kyowa Hakko Form Alliance
Alnylam Pharma Forms Joint Venture With Isis Pharma
Alnylam Pharma Amends Agreement With Medtronic
Biogen Idec Enters Into Agreement With Alnylam
Tekmira Amends Research Collaboration With Alnylam Pharma
Alnylam Pharma Amends Its Collaboration Agreement With Merck
Alnylam Pharma Enters Into Collaboration Agreement With USAMRIID
Alnylam Pharma Enters Into Research Agreement With Inex Pharma
Alnylam Enters Into Co-Development Agreement With Novartis
Alnylam Enters Into Agreement With Novartis
Alnylam Pharma Enters Into Collaboration With University Of Georgia
Alnylam Enters Into Agreement With Cystic Fibrosis Foundation
Alnylam Enters Into Agreement With Medtronic
Merck Enters Into An Agreement With Alnylam Pharma
Alnylam Enters Into Agreement With Cenix Bioscience
Bio-Rad Labs Enters Into An Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Inex Pharma
Alnylam Enters Into Licensing Agreement With Dharmacon
Alnylam Enters Into License Agreement With Hybridon
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Tekmira Pharma
The University of Queensland Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Mount Sinai School
Alnylam Pharma Enters Into Licensing Agreement With University of Queensland
Roche Expands Licensing Agreement With Alnylam
Alnylam Enters Into License Agreement With Koken
Alnylam Pharma Enters Into Licensing Agreement With Isis Pharma
Alnylam Pharma Enters Into Licensing Agreement With Calando Pharma
Takeda Pharma Enters Into Collaboration Agreement With Alnylam Pharma
Alnylam Pharma And Tekmira Pharma Enter Into Licensing Agreement
Alnylam Enters Into Agreement With Shanghai GenePharma
Alnylam Pharma Enter Into Licensing Agreement With GeneDesign
Roche Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement with Hayashi Kasei
Alnylam Enters Into Licensing Agreement With Inex Pharma
Alnylam Pharma Enters Into Licensing Agreement With Quark Pharma
Alnylam Enters Into Agreement With Calando
Alnylam Enters Into Agreement With Bioneer
Alnylam Enters Into Agreement With Immune Disease Institute
Alnylam Enters Into Agreements With Massachusetts Institute of Technology
Gen-Probe Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Pharma Enters Into Licensing Agreement With Integrated DNA Technologies
Alnylam Pharma Enters Into Licensing Agreement With QIAGEN
Alnylam And Isis Enter Into License Agreement With Stanford University
Alnylam Enters Into License Agreement With MWG Biotech
Nastech Pharma Enters Into Agreement With Alnylam Pharma
Alnylam Enters Into A Licensing Agreement With Sigma-Aldrich
Alnylam Enters Into License Agreement With Eurogentec
Alnylam Amends Its Agreements With Max Planck Society
Alnylam Enters Into Agreement With Ambion
Alnylam Enters Into Agreement With Benitec
Alnylam Pharma Enters Into Licensing Agreement With GeneCare Research Institute
Alnylam And Isis Enter Into Licensing Agreement With Max Planck Society
Isis Pharma Enters Into Licensing Agreement With Alnylam Pharma
Alnylam Enters Into License Agreement With RNAX
Alnylam Enters Into Licensing Agreement With Invitrogen
Alnylam Enters Into Licensing Agreement With Cell Signaling Technology
Alnylam Pharma Announces Underwriters' Exercise Of Over-Allotment Option For $93 Million
Alnylam Completes Private Placement Of $1 Million With Novartis
Tekmira Completes Private Placement Of $5 Million With Alnylam
Alnylam Pharma Completes Private Placement Of $5 Million
Alnylam Pharma Completes Public Offering Of $103 Million
Alnylam Completes Public Offering Of $67 Million
Alnylam Pharma Completes Private Placement Of $5 Million
Alnylam Pharma Completes IPO Of $35 Million

List of Figures
Alnylam Pharmaceuticals, Inc – Pipeline by Indication, 2012
Alnylam Pharmaceuticals, Inc – Pipeline by Stage of Development, 2012
Alnylam Pharmaceuticals, Inc – Monotherapy Products in Pipeline, 2012
Alnylam Pharmaceuticals, Inc – Pipeline By Therapeutic Class, 2012
Alnylam Pharmaceuticals, Inc - Pipeline By Target, 2012
Alnylam Pharmaceuticals, Inc – Pipeline By Route of Administration, 2012
Alnylam Pharmaceuticals, Inc - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Idenix Pharmaceuticals, Inc.
• Novell Sheds Light on Profitability, but Continues to Disappoint
• SAS
• Analysis of Yahoo! Inc
• Analysis of Google Inc
• Red Hat Turns Open Source into Enterprise Assets
• TDC A/S IT Sales Opportunities - 2008
• Kuehne and Nagel - IT Sales Opportunities - 2009
• Company Profile: Quanta Computer Inc.
• Max India Limited - IT Sales Opportunities - 2009